Positive Growth of Eli Lilly’s Taltz and Stabilization of Novartis’ Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift


EXTON, Pa., Oct. 10, 2019 /PRNewswire/ — Novartis’ Cosentyx was first approved by the FDA for the treatment of psoriasis in January 2015, followed by a label extension for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) a year later – snagging the first-to-market IL-17…


Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly